AIT to present AIT-RSV at Medical Meetings

Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings

 

Rehovot, Israel and New York, NY – April 21, 2015 – Advanced Inhalation Therapies Ltd (AIT), a leading anti-viral therapeutic company, announced that two abstracts have been accepted for oral presentations at two upcoming medical meetings: European Society for Pediatric Infectious Disease from May 12–16 in Leipzig, Germany and American Thoracic Society 2015 International Conference from May 15–20 in Denver, Colorado. The abstracts are currently available on the websites for each of the meetings.

The oral presentations will provide updated data from the Phase 2 clinical trial of the Company’s lead drug candidate, AIT-RSV.  AIT-RSV is a clinical stage drug candidate for the treatment of children with respiratory syncytial virus (RSV) and bronchiolitis.

 

Oral Presentation

  • Title: Intermittent, High-Dose Nitric Oxide Inhalation Therapy for Hospitalized 2-12 Month Old Infants with Bronchiolitis: A Double Blinded, Randomized Controlled Trial
  • Presenter: David Greenberg, MD, Professor of Pediatrics and Infectious Disease at Soroka Medical Center in Beer-Sheba, Israel, Chief Medical Officer of Advanced Inhalation Therapies and Investigator
  • Medical Meeting: European Society of Pediatric Infectious Disease
  • Session: Short Oral Presentation – Severe Bacterial and Viral Infections
  • Date & Time: Thursday, May 14, 2015, 1:30 pm to 3:30 pm

 

Oral Presentation

  • Title: Intermittent, High-Dose Nitric Oxide Inhalation Therapy For Hospitalized Infants With Bronchiolitis: A Double- Blinded, Randomized Controlled Trial
  • Presenter: Asher Tal, MD, Vice President of Clinical Development at Advanced Inhalation Therapies and Investigator
  • Medical Meeting: ATS – American Thoracic Society 2015 International Conference
  • Session: Late Breaking Mini Symposium: Novel Diagnostics and Therapeutics: Approaching Personalized Medicine in Pulmonary Disease
  • Date & Time: Monday, May 18, 2015, 9:30 am to 11:30 am

 

About RSV

RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract. RSV infects nearly every child at least once by the age of two and is a leading cause of hospitalization in children and in people with compromised immune systems. RSV infections typically result in cold-like symptoms but can lead to more serious respiratory illnesses such as croup, pneumonia, bronchiolitis, and in extreme cases, death. RSV infections in the pediatric population account for more than 175,000 hospitalizations per year in the U.S. In addition, RSV infection in infants has been linked to the development of childhood asthma.

 

About Advanced Inhalation Therapies

AIT is a biopharmaceutical company developing novel anti-viral therapeutics based on Nitric Oxide. The Company is applying its therapeutic expertise in NO to address significant medical needs, many of which cannot effectively be addressed with current standards of care, including small molecules and antibodies.  AIT is building a pipeline of Nitric Oxide therapeutics as it has completed a Phase II trial for the treatment of respiratory syncytial virus (RSV) infection and a Phase II trial for the treatment of cystic fibrosis. The Company’s leadership position in fundamental patents, technology, and know-how relating to NO has enabled it to develop a unique NO drug formulation for the treatment of RSV infection and Cystic Fibrosis.  AIT’s integrated proprietary system continuously monitors safety and efficacy parameters in patients.  The Company, founded in 2011, maintains global headquarters in Rehovot, Israel and has an additional operating unit in New York, NY. For more information, visit www.AIT-Pharm.com.

 

Forward-Looking Statements

Various statements in this release concerning our future expectations, plans, and prospects, including without limitation, statements concerning the use of Nitric Oxide therapeutics for the treatment of RSV and other viral disease and the availability of results of clinical trials and studies, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; and our short operating history; In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.

 

 

CONTACT INFORMATION

Amir Avniel, CEO, AIT
2600 Netherland Ave, Riverdale, NY
USA 10463
E-mail: amir@ait-pharm.com
Direct: 3473270394

 

Stephanie Carrington

Integrated Corporate Relations, Inc. (ICR): Redefining Strategic Communications

685 Third Avenue, 2nd Floor,

New York, NY 10017

Email: stephanie.carrington@icrinc.com

Direct: (646) 277-1282